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Data on the clinical burden of chronic spontaneous urticaria (CSU) and economic
consequences are lacking in France. To characterize the clinical and economic burden
of CSU in symptomatic patients despite treatment by analysing data of French patients
from the ASSURE-CSU study. ASSURE-CSU was an international observational study
that included CSU patients with symptoms that lasted for 12 months or more despite
treatment. Disease characteristics and healthcare resource use were obtained from
medical records. Data on disease history, health-related quality of life (HR-QoL), and
work productivity were collected from a patient survey. A total of 101 patients were
analysed (76.2% female; mean age: 48.9 years) with moderate to severe disease (UAS7
score ≥16) in 43.4% and angioedema in 72.3%. The mean (S.D.) total scores of Chronic
Urticaria Quality of Life (CU-QoL) and Dermatology Life Quality Index (DLQI) were
37.7 (22.3) and 9.7 (6.9), respectively, thus indicating a significant impact of the
disease on HR-QoL. Mean absenteeism and presenteeism were 6.4% and 20.8%,
respectively, with a mean loss of work productivity estimated at 20.7%. The mean
(S.D.) total direct cost of CSU was €2,397 per patient per year and was mainly driven
by therapies (€1,435) and inpatient costs (€859). The indirect costs for four weeks
were mainly presenteeism (€421) and loss of work productivity (€420). CSU
significantly impairs HR-QoL, which increases with the severity of the disease. The
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